BCL2 and acute myeloid leukemia: The hypomethylating agents (HMA) azacitidine (AZA) and decitabine (DEC) are used to treat AML patients unlikely to tolerate or respond to cytotoxic chemotherapy, recently in combination with the B-cell lymphoma-2 (Bcl-2) inhibitor venetoclax (VEN) (7).